Patent 10981994 was granted and assigned to Apollomics Inc on April, 2021 by the United States Patent and Trademark Office.
The present invention relates to antibodies and antigen-binding fragments thereof that bind to PD-1, and to methods of using such antibodies and antigen-binding fragments. For example, the present invention provides humanized anti-PD-1 antibodies and methods of use thereof.